Treatment resistance is when cancer does not respond to a drug. Cancer, including triple-negative MBC, often becomes resistant to a particular treatment over time. Alternatively, resistance may be present before treatment begins. Researchers are working to understand why resistance happens and to find new ways to overcome resistance. An important step in understanding treatment resistance is to identify biomarkers in people with treatment-resistant triple-negative breast cancer in clinical trials.
Read below to learn about current research efforts to overcome treatment resistance in triple-negative MBC.
Treatment Resistance in Triple-Negative MBC
- World Pharma News: Blocking a protein called P-gp may overcome resistance in triple-negative breast cancer
- Baylor College of Medicine: Multiple biomarkers may identify triple-negative breast cancer that is resistant to treatment and may suggest ways to overcome this resistance
- US Department of Defense Congressionally Directed Medical Research Programs: An experimental compound works with chemotherapy to overcome resistance in triple-negative breast cancer cells
- MD Anderson Cancer Center: Triple-negative breast cancer may be resistant to chemotherapy before treatment begins, and the cancer may develop new changes during treatment that enhance resistance
MBC Clinical Trials
- Metastatic Trial Search: Trials specifically for people with triple-negative MBC
- Metastatic Trial Search: Trials enrolling people with triple-negative MBC
- Metastatic Trial Search: Trials for Predicting Response to Treatment
Last Modified on January 2, 2024